Sentinel node imaging

Current Medical Imaging Reviews

Volumn 2, Issue 3, 2006, Pages 341-346

  Chakera, Annette H ^a   Drzewiecki, Krzysztof T ^a   Ingvar, Christian ^b   Steiniche, Torben ^c   Hesse, Birger ^d  

^a Mental Health Services CPH   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Breast cancer; Immunohistochemical staining; Lymphoscintigraphy; Micrometastases; SN probe detection

Indexed keywords

DYE; TRACER;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; COLLOID; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION; ISOTOPE LABELING; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHOSCINTIGRAPHY; MELANOMA; MORBIDITY; PRIORITY JOURNAL; SCINTILLATION CAMERA; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

EID: 33746874917     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340506777934589     Document Type: Article

References (54)

1. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232: 81-9.
2. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 22: 759-767.
3. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 3: 976-983.
4. Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph-node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998; 24: 104-9.
5. Keshtgar MR, Baum M. Axillary dissection over the years: where, to from here? World J Surg 2001; 25: 761-6.
6. Chakera AH, Drzewiecki KT, Eigtved A, Juhl BR. Sentinel node biopsy for melanoma: a study of 241 patients. Melanoma Res 2004; 14:521-6.
7. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23: 4312-21.
8. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathol 2004; 36: 478-84.
9. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
10. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000; 18: 2560-6.
11. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87: 484-9.
12. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91: 368-73.
13. Uren RF, Howman-Giles R, Thompson JF, et al. Interval nodes. The forgotten sentinel nodes in patients with melanoma. Arch Surg 2000; 135: 1168-1172.
14. McMasters KM, Wong SL, Chao C, Woo C, Edwards MJ. Defining the optimal surgeon experience for breast cancer sentinel lymph node (SLN) biopsy. A model for implementation of new surgical technique. Ann Surg 2001; 234: 292-300.
15. Bergqvist L, Sundberg R, Ryden S, Strand SE. The "critical colloid dose" in studies of reticuloendothelial function. J Nucl Med 1987; 28: 1424-9.
16. Mariani G, Erba P, Villa G, et al. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective., J Surg Oncol. 2004; 85: 112-22.
17. Chakera AH, Friis E, Hesse U, Al-Suliman N, Zerahn B, Hesse B. Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer. Eur J Nucl Med Mol Imaging 2005; 32: 286-93.
18. Tanis PJ, Nieweg OE, Valdés Olmos RA, Kroon BBR. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 2001; 192: 399-409.
19. Pijpers R, Collet GJ, Meijer S, Hoekstra OS. The impact of dynamic lymphoscintigraphy and gamma probe guidance of sentinel node biopsy in melanoma. Eur J Nucl Med 1995; 22: 1238-41.
20. Krynyckyi BR, Miner M, Ragonese JM, Firestone M, Kim CK, Machac J. Technical aspects of performing lymphoscintigraphy: optimization of methods used to obtain images. Clin Nucl Med 2000; 25: 978-85.
21. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186: 275-83.
22. Tanis PJ, van Sandick JW, Nieweg OE, et al. The hidden sentinel node in breast cancer. Eur J Nucl Med Mol Imaging 2002; 29: 305-11.
23. Tanis PJ, Valdes Olmos RA, Muller SH, Nieweg OE. Lymphatic mapping in patients with breast carcinoma: reproducibility of lymphoscintigraphic results. Radiology 2003: 228: 546-51.
24. Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 2005; 189: 236-9.
25. Pinero A, Illana, J, Garcia-Palenciano C, et al. Effect on oximetry of dyes used for sentinel lymph node biopsy. Arch Surg 2004; 139: 1204-7.
26. El-Tamer M, Komenaka IK, Curry S, Troxel AB, Ditkoff BA, Schnabel FR. Pulse oximeter changes with sentinel lymph node biopsy in breast cancer. Arch Surg 2003; 138: 1257-60.
27. Linehan DC, Hill AD, Akhurst T, et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999; 6: 450-4.
28. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. EORTC Melanoma Group. J Pathol 2003; 200: 314-9.
29. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004; 101: 2141-2.
30. Abrahamsen HN, Sorensen BS, Nexo E, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. Clin Cancer Res 2005; 11: 1425-33.
31. Werner JA, Dunne AA, Ramaswamy A, et al. The sentinel node concept in head and neck cancer: solution for the controversies in the NO neck? Head Neck 2004; 26: 603-11.
32. Kroon BK, Horenblas S, Meinhardt W, et al. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. Eur Urol 2005; 47: 601-6.
33. De Cicco C, Sideri M, Bartolomei M, et al. Sentinel node biopsy in early vulvar cancer. Br J Cancer 2000; 82: 295-9.
34. Roca I, Caresia AP, Gil-Moreno A, et al. Usefulness of sentinel lymph node detection in early stages of cervical cancer. Eur J Nucl Med Mol Imaging 2005; 32:1210-6.
35. Saha S, Dan AG, Viehl CT, Zuber M, Wiese D. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls. Cancer Treat Res 2005; 127: 105-22.
36. Zulfikaroglu. B, Koc M, Ozmen MM, Kucuk NO, Ozalp N, Aras G. Intraoperative lymphatic mapping and sentinel lymph node biopsy using radioactive tracer in gastric cancer. Surgery 2005; 139: 899-904.
37. Maccauro M, Lucignani G, Aliberti G, et al. Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer. Eur J Nucl Med Mol Imaging 2005: 32: 569-74.
38. Liptay MJ. Sentinel lymph node mapping in lung cancer. Cancer Treat Res 2005; 127: 141-50.
39. Sherif A, De La Torre M, Malmstrom PU, Thorn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J Urol 2001; 166: 812-5.
40. Wawroschek F, Vogt H, Wengenmair H, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70: 303-10.
41. Satoh M, Ito A, Kaiho Y, et al. Intraoperative, radio-guided sentinel lymph node mapping in laparoscopic lymph node dissection for Stage I testicular carcinoma. Cancer 2005; 103: 2067-72.
42. Testori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Res 2005; 15: 191-8.
43. Nori J, Bazzocchi M, Boeri C, et al. Role of axillary lymph node ultrasound and large core biopsy in the preoperative assessment of patients selected for sentinel node biopsy. Radiol Med (Torino) 2005; 109: 330-44.
44. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography-Computed Tomography: Experience on a 32-Channel System. Invest Radiol 2005; 40: 743-753.
45. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 2005; 174: 923-7.
46. Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233: 449-56.
47. Stretch J, Somorjai R, Bourne R, et al. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann Surg Oncol 2005; 12: 943-9.
48. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104: 570-9.
49. Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11: 846-53.
50. Fehr MK, Hornung R, Varga Z, et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004; 10: 89-93.
51. Sironi S, Buda A, Picchio M, et al. Lymph Node Metastasis in Patients with Clinical Early-Stage Cervical Cancer: Detection with Integrated FDG PET/CT. Radiology Nov 2005 (E-pub).
52. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005; 236: 1011-9.
53. Chakera AH, Madsen J, Kristjansen PEG, et al. Immunoscintigraphy in a human xenograft breast cancer model in mice. Accepted abstract for "Radioactive Isotopes in Clinical Medicine and Research", 27th International Symposium, Bad Gastein, Austria, January 2006.
54. Morton DL, Thompson JF, Cochran AJ, Essner P, Elashoff R. Multicenter Selective Lymphadenectomy Trial Group. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma. Abstract from ASCO 2005 Meeting.